Sanjiv Singh

Dr. Sanjiv Singh

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
SSSanjiv Singh
Sanjiv Singh
DAD. Anshita
D. Anshita
VRV. Ravichandiran
V. Ravichandiran

15 January 2019 in Toxicology Mechanisms and Methods
Verified
Journal Article
Closed access
SSSanjiv Singh
Sanjiv Singh
Zinc oxide (ZnO) is the most commonly used nanoparticles among different nanoparticles. Its applications ranged from personal care products, sensors, antibacterial creams and biomedical applications. The broad range of applications raises concern in regards to their potential toxicity. Therefore it is required to understand their toxicity mechanism and pattern on various levels. The primary aim of this review is to summarize the cytotoxicity, genotoxicity, neurotoxicity and developmental toxicity of ZnO nanoparticles in various kinds of cells in vitro and in vivo. Literatures available on Zinc oxide nanoparticles toxicity suggest that dissolution, organism dependent cellular uptake, generation of reactive oxygen species and induced inflammatory responses seem to be common factors which govern the toxicity of zinc oxide nanoparticles.

14 March 2024 in Ageing Research Reviews
Verified
Journal Article
Closed access
PRPratik Shankar Rakshe
Pratik Shankar Rakshe
BDBhaskar Jyoti Dutta
Bhaskar Jyoti Dutta
SCShivani Chib
Shivani Chib
NMNiyogita Maurya
Niyogita Maurya
SSSanjiv Singh
Sanjiv Singh

12 March 2023 in Health Sciences Review
Verified
Journal Article
Open access
ARAdarsh Ray
Adarsh Ray
KMKrushna Ch. Maharana
Krushna Ch. Maharana
SMSarasa Meenakshi
Sarasa Meenakshi
SSSanjiv Singh
Sanjiv Singh

1 February 2021 in Heliyon
Verified
Journal Article
Open access
SSSanjiv Singh
Sanjiv Singh
DNDevarapati Nagalakshmi
Devarapati Nagalakshmi
KSK.K. Sharma
K.K. Sharma
VRV. Ravichandiran
V. Ravichandiran
The transcription factor Nrf2 (nuclear factor-erythroid 2 p45-related factor 2) play a crucial role in cellular redox and metabolic system. Activation of Nrf2 may be an effective therapeutic approach for neuroinflammatory disorders, through activation of antioxidant defences system, lower the inflammation, line up the mitochondrial function, and balancing of protein homeostasis. Various recent studies revealed that many of active substance obtained from plants have been found to activate the Nrf2 and to exert neuroprotective effects in various experimental models, raising the possibility that activation of Nrf2 may be an effective therapeutic approaches for neuroinflammatory disorders. The objective of this review was to evaluate the neuroprotective property of natural substance against neuroinflammatory disorders by reviewing the studies done till today. The outcomes of various in vitro and in vivo examinations have shown that natural compounds producing neuroprotective effects in neuronal system via activation of Nrf2. Herein, we also reviewed the studies to understand the role of Nrf2 for curing CNS disorders. Here we can conclude, herbal/natural moieties having potency to fight and prevent from neuroinflammatory disorders due to their abilities to activate Nrf2 pathway.

17 September 2019 in Current Drug Safety
Verified
Journal Article
Open access
PDF file
SSSanjiv Singh
Sanjiv Singh
AKAbhishek Kumar
Abhishek Kumar
Background: Cyclophosphamide (CPA) is the most widely prescribed cancer chemotherapeutic agent which shows serious neurotoxic side effect. Generation of reactive oxygen species at the cellular level is the basic mechanism of cyclophosphamide induced neurotoxicity. Edaravone is the synthetic drug used for brain stroke and has potent antioxidant property.Objective: This study aimed to investigate the effect of edaravone on neurobehavioral and neuropathological alteration induced by cyclophosphamide in male rats.Methods: Twenty eight Sprague-Dawley rats were equally divided into four groups of seven rats in each. The control group received saline, and other groups were given CPA intraperitoneally (100 mg/kg), CPA (100 mg/kg) intraperitoneally + Edaravone (10 mg/kg) orally, or Edaravone (10 mg/kg) orally for one month.Results: Our data showed that CPA significantly elevated brain AChE activity in the hippocampal region. A decrease in the total antioxidant capacity and a reduction in the CAT, SOD, and GPX activity occurred in the brains of the rats exposed to CPA. CPA-treated rats showed a significant impairment in long-termmemory and motor coordination. These results were supported by histopathological observations of the brain. Results revealed that administration of edaravone reversed AChE activity alternation and ameliorated behavioral and histopathological changes induced by CPA.Conclusion: This study suggests that co-administration of edaravone with cyclophosphamide may be a useful intriguing therapeutic approach to overcome cyclophosphamide induced neurotoxicity.